ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Lymmf
|
449 |
137K |
21 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
449
|
137K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Lymmf
|
226 |
71K |
1 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
71K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
29 Feb HY Conference Call Transcript
|
|
Lymmf
|
23 |
7.7K |
5 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
23
|
7.7K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Lymmf
|
9.2K |
2.6M |
7 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
9.2K
|
2.6M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Lymmf
|
9.2K |
2.6M |
4 |
22/01/24 |
22/01/24 |
ASX - By Stock
|
9.2K
|
2.6M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Lymmf
|
17K |
6.5M |
7 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
17K
|
6.5M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Lymmf
|
4.8K |
2.3M |
11 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
4.8K
|
2.3M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Taken up the entitlement?
|
|
Lymmf
|
544 |
129K |
9 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
544
|
129K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: CEO Presentation to 2023 Annual General Meeting
|
|
Lymmf
|
114 |
36K |
9 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
114
|
36K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Files for FDA Designations in Congenital Heart Disease
|
|
Lymmf
|
68 |
22K |
18 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
68
|
22K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Lymmf
|
17K |
6.5M |
16 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
17K
|
6.5M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Lymmf
|
9.2K |
2.6M |
18 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
9.2K
|
2.6M
|
18
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Lymmf
|
3.4K |
1.1M |
13 |
22/07/23 |
22/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Lymmf
|
3.4K |
1.1M |
20 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Lymmf
|
3.4K |
1.1M |
13 |
28/06/23 |
28/06/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Third Quarter Results Presentation
|
|
Lymmf
|
55 |
21K |
21 |
29/05/23 |
29/05/23 |
ASX - By Stock
|
55
|
21K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Media News
|
|
Lymmf
|
221 |
95K |
2 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
221
|
95K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Media News
|
|
Lymmf
|
221 |
95K |
8 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
221
|
95K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
Lymmf
|
1.0K |
380K |
69 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
380K
|
69
|
|
ASX - By Stock
|
MSB |
Re:
DREAM HF Trial Video
|
|
Lymmf
|
99 |
33K |
3 |
05/02/23 |
05/02/23 |
ASX - By Stock
|
99
|
33K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
DREAM HF Trial Video
|
|
Lymmf
|
99 |
33K |
13 |
05/02/23 |
05/02/23 |
ASX - By Stock
|
99
|
33K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
DREAM HF Trial Video
|
|
Lymmf
|
99 |
33K |
8 |
03/02/23 |
03/02/23 |
ASX - By Stock
|
99
|
33K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Lymmf
|
9.2K |
2.6M |
6 |
23/01/23 |
23/01/23 |
ASX - By Stock
|
9.2K
|
2.6M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Lymmf
|
9.2K |
2.6M |
9 |
23/01/23 |
23/01/23 |
ASX - By Stock
|
9.2K
|
2.6M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Biotech Showcase 2023 Presentation in San Francisco
|
|
Lymmf
|
179 |
69K |
4 |
19/01/23 |
19/01/23 |
ASX - By Stock
|
179
|
69K
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2023 - awaiting for Ryoncil approval
|
|
Lymmf
|
618 |
233K |
14 |
13/01/23 |
13/01/23 |
ASX - By Stock
|
618
|
233K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Submits New Information to FDA IND File for SR-aGVHD
|
|
Lymmf
|
576 |
201K |
28 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
576
|
201K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Voluntary Suspension
|
|
Lymmf
|
332 |
117K |
17 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
332
|
117K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
How low can we go?
|
|
Lymmf
|
184 |
39K |
12 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
184
|
39K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Chronic Lower Back Pain - the sleeping giant.
|
|
Lymmf
|
484 |
145K |
19 |
19/06/22 |
19/06/22 |
ASX - By Stock
|
484
|
145K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Host KOL Event on Chronic Low Back Pain
|
|
Lymmf
|
132 |
39K |
18 |
19/06/22 |
19/06/22 |
ASX - By Stock
|
132
|
39K
|
18
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2022 - The road to commercialisation
|
|
Lymmf
|
1.5K |
492K |
6 |
08/04/22 |
08/04/22 |
ASX - By Stock
|
1.5K
|
492K
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2022 - The road to commercialisation
|
|
Lymmf
|
1.5K |
492K |
8 |
08/04/22 |
08/04/22 |
ASX - By Stock
|
1.5K
|
492K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
rurenga
|
|
Lymmf
|
62 |
22K |
23 |
28/03/22 |
28/03/22 |
ASX - By Stock
|
62
|
22K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Director Appointment
|
|
Lymmf
|
213 |
58K |
7 |
24/03/22 |
24/03/22 |
ASX - By Stock
|
213
|
58K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Short Squeeze
|
|
Lymmf
|
505 |
159K |
5 |
22/03/22 |
22/03/22 |
ASX - By Stock
|
505
|
159K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Lymmf
|
4.7K |
1.0M |
17 |
21/02/22 |
21/02/22 |
ASX - By Stock
|
4.7K
|
1.0M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
Lymmf
|
151 |
40K |
20 |
31/01/22 |
31/01/22 |
ASX - By Stock
|
151
|
40K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Presents at Edison Group Global Healthcare Conference
|
|
Lymmf
|
267 |
64K |
6 |
25/01/22 |
25/01/22 |
ASX - By Stock
|
267
|
64K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Silviu Itescu The Legend
|
|
Lymmf
|
880 |
211K |
2 |
06/01/22 |
06/01/22 |
ASX - By Stock
|
880
|
211K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Silviu Itescu The Legend
|
|
Lymmf
|
880 |
211K |
14 |
05/01/22 |
05/01/22 |
ASX - By Stock
|
880
|
211K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
|
|
Lymmf
|
211 |
72K |
18 |
01/01/22 |
01/01/22 |
ASX - By Stock
|
211
|
72K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
|
|
Lymmf
|
211 |
72K |
22 |
31/12/21 |
31/12/21 |
ASX - By Stock
|
211
|
72K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Lymmf
|
408 |
122K |
3 |
18/12/21 |
18/12/21 |
ASX - By Stock
|
408
|
122K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Lymmf
|
408 |
122K |
22 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
408
|
122K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
Lymmf
|
373 |
111K |
15 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
373
|
111K
|
15
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Lymmf
|
10K |
3.0M |
12 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
10K
|
3.0M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
Lymmf
|
373 |
111K |
9 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
373
|
111K
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Lymmf
|
10K |
3.0M |
20 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
10K
|
3.0M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Lymmf
|
516 |
154K |
20 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
516
|
154K
|
20
|
|